Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and patients experience problems with cognitive and emotional processes as well. SCAN, the somato-cognitive action network identified in 2023, could reshape the definition of PD. Treating this circuit can improve outcomes. Read More
Newco ALTx Therapeutics Ltd. has launched with a £12.55 million (US$17.1 million) seed round to develop inhibitors of the alternative lengthening of telomeres (ALT) pathway, by which 10% to 15% of cancers become immortal. Read More
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in lipid nanoparticles. Read More
Researchers at Tangram Therapeutics Inc. have presented preclinical safety and efficacy data for TGM-148 in a model of von Willebrand disease. Read More
Jeil Pharmaceutical Co. Ltd. has disclosed dihydrothiopyranopyrimidine compounds acting as phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of inflammatory joint disease, neurological disorders and more. Read More
Laminins are extracellular matrix (ECM) glycoproteins that preserve the structural and functional integrity of tissues. These heterotrimeric proteins, composed of one α, β and γ chain encoded by different genes, provide mechanical support, facilitate cell adhesion and maintain tissue organization and stability. Read More
Researchers from the Institut National De La Sante Et De La Recherche Medicale, Universite de Bordeaux and Universite de Paris Cite have reported indane 1,3-dione derivatives acting as furin (PACE; PCSK3) inhibitors potentially useful for the treatment of cancer. Read More
Tyk Medicines Inc. has identified N-acetyl-β-D-glucosaminidase (O-GlcNAcase; OGA) inhibitors described as potentially useful for the treatment of cancer, metabolic diseases, Alzheimer’s disease and progressive supranuclear palsy. Read More
Hidradenitis suppurativa (HS) is a chronic autoinflammatory condition affecting the skin, the genetic mechanisms of which are not well understood. A group of researchers set out to explore the genetic background of familial HS by performing whole-exome sequencing on genomic DNA from patients. Read More
Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered new proprotein convertase subtilisin/kexin-type 9 (PCSK9) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase dual inhibitors. They are described as potentially useful for the treatment of hypercholesterolemia. Read More
The melanin-concentrating hormone (MCH) is one of the most potent central stimulators of feeding and regulates energy balance. Therefore, agonists of the melanin-concentrating hormone MCH1 receptor could offer potential for weight management. Moreover, the role of MCH1 receptor in syndromic obesity has recently been uncovered. Read More
